Marjorie A. Peraza - Concepedia

Author

Marjorie A. Peraza

University of Arizona

Also Known As

M A Peraza, M Peraza, M.A. Peraza, Marjorie A. Peraza, Marjorie Peraza

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of Arizona Pfizer (United States)

About

Marjorie A. Peraza is an author at University of Arizona specializing in medicine, pathology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	112
2	Health Sciences	1	1	37
3	Biostatistics	1	1	37
4	Immunology	1	1	30
5	Nephrology	1	1	45

Marjorie A. Peraza

Publications

437

Citations

H-Index

Page 1

	Year	Citations
Ligand Activation of Peroxisome Proliferator–Activated Receptor β Inhibits Colon Carcinogenesis Holly E Marin, Marjorie A. Peraza, Andrew N. Billin, Cancer Research	2006	133
Effects of Micronutrients on Metal Toxicity Marjorie A. Peraza, Felix Ayala-Fierro, David S. Barber, Environmental Health Perspectives	1998	123
Toxicity and metabolism of subcytotoxic inorganic arsenic in human renal proximal tubule epithelial cells (HK-2) Marjorie A. Peraza, D E Carter, A. Jay Gandolfi Cell Biology and Toxicology UrologyMetalloid ContaminationPathologyToxicologySubcytotoxic Inorganic Arsenic	2003	45
Morphological and functional alterations in human proximal tubular cell line induced by low level inorganic arsenic: evidence for targeting of mitochondria and initiated apoptosis Marjorie A. Peraza, Douglas W. Cromey, Barb Carolus, Journal of Applied Toxicology	2006	41
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation Helen Prior, Paul Baldrick, Sonja Beken, Regulatory Toxicology and Pharmacology Drug TargetDrug ModalityPathologyToxicology TestingGeneral Toxicology Studies	2020	37
Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086 Chuenlei Parng, Pratap Singh, Debra D. Pittman, Journal of Pharmaceutical Sciences Translational MedicinePharmacokinetic ModelingPharmacodynamicsPharmacological StudyMedicine	2018	30
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab Marjorie A. Peraza, Karen E. Rule, Michael H.I. Shiue, Regulatory Toxicology and Pharmacology	2018	28

Page 1